Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · IEX Real-Time Price · USD
1.700
+0.050 (3.03%)
At close: May 2, 2024, 4:00 PM
1.690
-0.010 (-0.59%)
After-hours: May 2, 2024, 7:59 PM EDT

Lexicon Pharmaceuticals Revenue

Lexicon Pharmaceuticals had revenue of $2.31M in the twelve months ending March 31, 2024, with 1,734.13% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.13M with 4,608.33% year-over-year growth. In the year 2023, Lexicon Pharmaceuticals had annual revenue of $1.20M with 766.19% growth.

Revenue (ttm)
$2.31M
Revenue Growth
+1,734.13%
P/S Ratio
181.13
Revenue / Employee
$8,109
Employees
285
Market Cap
418.60M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20231.20M1.07M766.19%
Dec 31, 2022139.00K-159.00K-53.36%
Dec 31, 2021298.00K-23.70M-98.76%
Dec 31, 202024.00M-298.08M-92.55%
Dec 31, 2019322.07M258.86M409.54%
Dec 31, 201863.21M-28.48M-31.06%
Dec 31, 201791.69M12.43M15.69%
Dec 31, 201679.26M-50.76M-39.04%
Dec 31, 2015130.01M107.16M468.89%
Dec 31, 201422.85M20.63M928.53%
Dec 31, 20132.22M1.13M104.04%
Dec 31, 20121.09M-760.00K-41.10%
Dec 31, 20111.85M-3.06M-62.33%
Dec 31, 20104.91M-5.79M-54.13%
Dec 31, 200910.70M-21.62M-66.89%
Dec 31, 200832.32M-17.80M-35.51%
Dec 31, 200750.12M-22.68M-31.15%
Dec 31, 200672.80M-2.88M-3.81%
Dec 31, 200575.68M13.94M22.58%
Dec 31, 200461.74M18.90M44.12%
Dec 31, 200342.84M7.64M21.70%
Dec 31, 200235.20M4.62M15.12%
Dec 31, 200130.58M16.12M111.47%
Dec 31, 200014.46M9.72M205.17%
Dec 31, 19994.74M2.50M111.34%
Dec 31, 19982.24M1.27M131.66%
Dec 31, 1997967.74K--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Revance Therapeutics 234.04M
GeneDx Holdings 202.57M
Anika Therapeutics 166.66M
ADC Therapeutics 69.56M
MaxCyte 41.29M
Mersana Therapeutics 36.86M
Cartesian Therapeutics 26.00M
Revenue Rankings